Reading NEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NEO free→Reading NEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NEO free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been steady, and it has a capital-friendly stance. Risk is high, and the sector backdrop is a headwind, which may affect performance compared to sector peers, where it is typical. Peer multiples imply a price roughly in line with where it trades (about fair); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $11.09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $11 NEO trades at 2× p/s, below its 2× p/s peer median. Our $11 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 1% below a flat-multiple fair value, below our forecast of about 13%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.23x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.03 → $0.03 (-2.3% / 30d). 0 raised, 1 cut, 11 covering analysts.
0 upgrades, 0 downgrades / 30d. 67% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$230.
How much price usually moves either way.
On a bad day, this stock has moved -$509.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,561.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Better operating income means the company is losing less money. This may help investors feel good.
Confirms:Q2 operating income improves compared to last year. It is getting closer to breaking even.
Disproves:Q2 operating income gets worse or stays negative.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NEO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 15, 2026, NeoGenomics, Inc. (the “Company”) issued a press release relating to the commencement of its proposed offering of convertible senior notes due 2032 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible Notes Offering”). A copy of the press release relating to the Convertible Notes Offering is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorpor…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2015-Q3, 2016-Q1, 2016-Q2, 2016-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NEO NeoGenomics Laboratories, Inc. | Typical Show detailsSector percentile: 38 of 100 | fair | high |
CVS CVS Health | Typical Show detailsSector percentile: 64 of 100 | fair | moderate |
CI Cigna | Above typical Show detailsSector percentile: 92 of 100 | inexpensive | moderate |
DGX Quest Diagnostics | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
LH Labcorp | Above typical Show detailsSector percentile: 79 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue through clinical revenue growth and innovative product launches.
Introduce new cancer testing solutions to enhance market differentiation and address unmet needs.
Focus on reducing operating losses and improving overall operating income.
Focus on increasing gross profit through strategic pricing and cost control.
Why it matters: This growth rate shows that more people want NeoGenomics' cancer tests. It shows the company can keep growing in a tough market.
Confirms:Q2 revenue growth meets or exceeds 10% year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
Why it matters: Higher adjusted EBITDA means more profits and better efficiency. They are keeping costs down while increasing revenue.
Confirms:Adjusted EBITDA in Q2 is over $10 million.
Disproves:Adjusted EBITDA in Q2 falls below $5 million.
Why it matters: Steady growth in clinical revenue shows strong demand for NeoGenomics' services. It shows their new products are working well.
Confirms:Clinical revenue growth in Q2 is above 10% year over year.
Disproves:Clinical revenue growth in Q2 drops below 5% year over year.
Why it matters: The launch's success could reach a $20 billion market. It shows NeoGenomics can create new ideas and earn more money.
Confirms:Clinicians like the RaDaR ST assay. Sales numbers are strong so far.
Disproves:Low adoption rates or bad feedback from clinicians about the RaDaR ST assay.
Why it matters: Continued revenue growth shows the company is expanding. This can improve market perception.
Confirms:Q2 revenue grows year over year, surpassing $186.7M.
Disproves:Q2 revenue growth slows or declines.
Why it matters: Higher operating income is important. It helps the company make money and gain investor trust.
Confirms:Operating income gets much better from the current loss of $18 million.
Disproves:Operating income stays negative or gets worse in the next quarters.
Why it matters: Changes in leadership can change company plans and results. This may affect how investors feel.
Confirms one read:New leadership brings a clear strategic plan that improves performance.
Confirms the other:Leadership change leads to confusion or lack of direction.
Why it matters: Higher gross profit means the company makes more money. This can bring in more investors.
Confirms:Q2 gross profit increases year over year, exceeding $80.9M.
Disproves:Q2 gross profit declines or stays below $80.9M.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 21, 2026, NeoGenomics, Inc. (the "Company") held an annual meeting (the "Annual Meeting") of its stockholders. At the Annual Meeting, stockholders approved an amendment (the "Amendment") to the Company's 2023 Equity Incentive Plan (the "Equity Incentive Plan") to increase the number of shares authorized for issuance thereunder by 5,000,000 s…
Results of Operations and Financial Condition. On April 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Results of Operations and Financial Condition. On February 17, 2026 , NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2025 and full year ended December 31, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of th…